Antibody molecules typically comprise two immunoglobulin light chains covalently bound to a pair of heavy chains. Immunoglobulin light chains occur in two types, designated by the Greek letters kappa and lambda. Kappa and lambda light chains are approximately 250 amino acids in length with an average mass of about 25 kDa. The ratio of kappa to lambda found in the immunoglobulin population varies by species.
Specificity
Reacts with human lambda light chains. Absorbed for human myeloma proteins with kappa light chains.
The antibody reacts with human lambda light chains as demonstrated by ELISA and flow cytometry.
Immunogen
Epitope: Ig lambda chain
Prepared from pooled antisera from goats hyperimmunized with human myeloma proteins with kappa light chains.
Application
Detect Human Ig λ chain using this Goat anti-Human Ig λ chain Antibody validated for use in ELISA.
Research Category Secondary & Control Antibodies
Research Sub Category Fragment Specific Secondary Antibodies
Physical form
Affinity Chromatography
Purified by affinity chromatography on pooled human Igs with lambda light chains covalently linked to agarose. Liquid in 1.0 mL of 100 mM borate buffered saline, pH 8.2.
Storage and Stability
Maintain refrigerated at 2°-8°C under sterile conditions for up to twelve months from date of receipt.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
The Journal of biological chemistry, 292(6), 2328-2344 (2016-12-30)
Intervention into amyloid deposition with anti-amyloid agents like the polyphenol epigallocatechin-3-gallate (EGCG) is emerging as an experimental secondary treatment strategy in systemic light chain amyloidosis (AL). In both AL and multiple myeloma (MM), soluble immunoglobulin light chains (LC) are produced
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
